RUCAPARIB CAMSYLATE

Search structure
Trade Names:
Synonyms:
Status: Approved (2016)
Entry Type: Small molecule
Molecule Category: Salt
UNII: 41AX9SJ8KO
Parent Compound: RUCAPARIB

Structure
InChI Key INBJJAFXHQQSRW-STOWLHSFSA-N
Smile CC1(C)[C@@H]2CC[C@@]1(CS(=O)(=O)O)C(=O)C2.CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1
InChI
InChI=1S/C19H18FN3O.C10H16O4S/c1-21-10-11-2-4-12(5-3-11)18-14-6-7-22-19(24)15-8-13(20)9-16(23-18)17(14)15;1-9(2)7-3-4-10(9,8(11)5-7)6-15(12,13)14/h2-5,8-9,21,23H,6-7,10H2,1H3,(H,22,24);7H,3-6H2,1-2H3,(H,12,13,14)/t;7-,10-/m.1/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C29H34FN3O5S
Molecular Weight 555.67
AlogP 2.98
Hydrogen Bond Acceptor 2.0
Hydrogen Bond Donor 3.0
Number of Rotational Bond 3.0
Polar Surface Area 56.92
Molecular species BASE
Aromatic Rings 3.0
Heavy Atoms 24.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR PARP 1, 2 and 3 inhibitor FDA

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Ovarian Neoplasms 4 D010051 FDA
Prostatic Neoplasms 3 D011471 ClinicalTrials
Neoplasms 1 D009369 ClinicalTrials

Related Entries

Scaffolds

Parent

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Gastrointestinal disorders
19.38
General disorders and administration site conditions
16.58
Investigations
12.45
Nervous system disorders
8.52
Injury, poisoning and procedural complications
6.08
Respiratory, thoracic and mediastinal disorders
4.83
Skin and subcutaneous tissue disorders
4.28
Musculoskeletal and connective tissue disorders
3.48
Metabolism and nutrition disorders
3.47
Psychiatric disorders
3.3
Cardiac disorders
3.27
Blood and lymphatic system disorders
2.83
Vascular disorders
2.57
Infections and infestations
2.45
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
2.2

Cross References

Resources Reference
ChEBI 134692
ChEMBL CHEMBL3833368
FDA SRS 41AX9SJ8KO
PubChem 121490161
CONTENTS